慢性胃食管反流病在瑞典的RefluxStop成本效益分析及相关治疗替代方案

数据集获取（Figshare）

• 源站标题：A cost-effectiveness analysis of RefluxStop against relevant therapeutic alternatives for chronic gastroesophageal reflux disease in Sweden
• DOI：10.6084/m9.figshare.27266280.v1
• 发布日期：2024-10-21
• 文件数：1 个
• 文件总体积：28.03 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/A_cost-effectiveness_analysis_of_RefluxStop_against_relevant_therapeutic_alternatives_for_chronic_gastroesophageal_reflux_disease_in_Sweden/27266280

命令行下载

curl -L -o "ierp_a_2417774_sm9536.odt" "https://ndownloader.figshare.com/files/49889442"

文件清单

• ierp_a_2417774_sm9536.odt（28.03 KB）

文件总体积 28.03 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

The standard treatment for gastroesophageal reflux disease (GERD) is proton pump inhibitors (PPIs). In selected cases, Nissen fundoplication is offered as a surgical treatment option, but alternative endoscopic and minimally invasive surgical alternatives are emerging. RefluxStop is a new technology for the treatment of GERD.
A cost-effectiveness analysis of RefluxStop in comparison to PPI therapy and Nissen fundoplication in the Swedish healthcare setting was conducted using a Markov model and available comprehensive population and clinical trial-based long-term data. Benefits were measured in quality-adjusted life-years (QALYs). Uncertainty was determined by deterministic and probabilistic sensitivity analyses.
The base case incremental cost-effectiveness ratios (ICERs) for RefluxStop in comparison to PPIs and Nissen fundoplications were SEK 48,152 (€ 4,531) and SEK 62,966 (€ 5,925) per QALY gained, respectively. At a cost-effectiveness threshold of SEK 500,000 per QALY gained, RefluxStop has a high likelihood of being cost-effective, with probabilities of 96% and 100% against Nissen fundoplication and PPIs, respectively. The results of the model remained robust with sensitivity analysis.
RefluxStop may offer a highly cost-effective long-term treatment alternative for chronic GERD patients over lifelong PPI therapy, but also in comparison with laparoscopic Nissen fundoplication.
Gastroesophageal reflux disease (GERD) is typically managed by proton pump inhibitor (PPI)-based medical management or antireflux surgery (i.e. Nissen fundoplication) in selected cases. However, alternative endoscopic and minimally invasive surgical alternatives have emerged. RefluxStop is a novel implantable device that aims to treat chronic GERD. We performed a cost-effectiveness analysis of RefluxStop from the perspective of the Swedish healthcare system including available treatment options in Sweden (i.e. PPI therapy and Nissen fundoplication). Benefits were measured using quality-adjusted life-years (QALYs). At the cost-effectiveness threshold of SEK 500,000 per QALY gained for Sweden, RefluxStop demonstrated a high likelihood of cost-effectiveness, with probabilities of 96%

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.27266280.v1（source: https://tandf.figshare.com/articles/dataset/A_cost-effectiveness_analysis_of_RefluxStop_against_relevant_therapeutic_alternatives_for_chronic_gastroesophageal_reflux_disease_in_Sweden/27266280）。